PvP Biologics is developing an oral enzyme for the treatment of celiac disease. Our mission is to develop a highly-effective therapeutic product to reduce the burden of living with this disease. Towards this end, we are advancing a product candidate designed to break down the immuno-reactive parts of gluten in the stomach and thereby avoid the painful symptoms and damage done in the small intestine from accidental gluten ingestion.Affecting an estimated 2.4 million Americans, celiac disease is significantly more common than inflammatory bowel disease and is associated with acute gastrointestinal symptoms, malnutrition, and increased mortality. The disease is currently treated by a gluten-free diet, which is costly and challenging to maintain strict compliance. Many patients continue to report persistent symptoms despite adhering to a gluten-free diet.The technology was invented at the Institute for Protein Design at University of Washington and exclusively in-licensed by PvP Biologics. We have corporate offices in San Diego and research laboratories in Seattle.

Takeda

Sahsen Ventures

PvP Biologics, Inc.

Specializes in developing therapeutic vaccines for celiac disease

ImmusanT

Engaged in the development of novel medicines for autoimmune and inflammatory diseases

Innovate Biopharmaceuticals, Inc.

Focused on developing diagnostics and therapeutics for celiac disease

ImmunogenX

PvP Biologics is a biotechnology company focused on developing an oral enzyme for the treatment of celiac disease, which affects an estimated 2.4 million Americans. The technology was invented at the University of Washington’s Institute for Protein Design.

PvP Biologics

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

financial_statements

network_onboarding

company_summary

signals

regulatory_analysis

industry_analysis

swot_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

news_advanced

news_impact_assignment_advanced

news_processing_advanced

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom	Mar 8, 2024 8:22 AM	04d591e7
news impact assignment basic	general	Mar 8, 2024 8:22 AM	b68f74c5
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 8, 2024 8:22 AM	46df37fd
company summary	general
signals	general	Mar 8, 2024 8:22 AM	06ad71e4
news advanced	general
news impact assignment advanced	general
news processing advanced	general
peers	general	Mar 8, 2024 8:22 AM	93c95538
news basic	general	Mar 8, 2024 8:22 AM	133cd8bc
events	markdown
bundesanzeiger	filings
financial statements	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
swot analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
customer profile	customers

COM:PVPBIO

PvP Biologics